KOD vs USAC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KOD and USAC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KOD and USAC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Kodiak Sciences is a Palo Alto based biotechnology company developing therapies for high-prevalence retinal diseases such as diabetic retinopathy, wet age-related macular degeneration (wet AMD), and macular edema. Its programs are built on an antibody biopolymer conjugate (ABC) platform intended to extend how long a single injection lasts in the eye. The lead candidate, tarcocimab tedromer (branded Zenkuda), delivered positive Phase 3 GLOW2 data in diabetic retinopathy in early 2026, while additional Phase 3 studies (DAYBREAK in wet AMD with KSI-501, and PEAK and PINNACLE for KSI-101 in macular edema secondary to inflammation) are reading out into 2027.

Full KOD guide

USA Compression Partners owns a fleet of natural gas compression packages and rents them to producers, processors, gatherers, and pipeline operators under fixed monthly fee contracts. The work is measured in horsepower, and the partnership focuses on the large midstream end of it rather than small wellhead units. At June 30, 2026 the fleet stood at ~4.95 million horsepower, of which ~4.46 million was revenue-generating across ~6,508 compression units, at average utilization of ~92.0%. It reports as a single segment. Headquarters is in Dallas, and USAC Management had ~885 full-time employees at the end of 2025, with another ~594 added through the January 2026 purchase of J-W Power Company. Energy Transfer owns 100% of the general partner and ~46.1 million common units, roughly a ~32% limited partner interest, and supplies shared back-office staff.

Full USAC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• KOD drivers: Multi-indication Phase 3 pipeline; Durability-focused ABC platform.
• USAC drivers: Contracted horsepower and pricing; J-W Power integration.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a pre-revenue clinical-stage biotech, Kodiak is exposed to binary trial risk, and a single failed Phase 3 readout can move the stock sharply, as the 2021 wet AMD failure demonstrated. For USAC, utilization fell to ~92.0% from ~94.4% a year earlier while fleet horsepower grew ~28.3%, which is what adding capacity faster than it gets contracted looks like.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KOD if you believe its drivers more; USAC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KOD and USAC guides.

KOD. Kodiak has no product revenue and posts steady net losses, so traditional earnings multiples do not apply and valuation reflects pipeline expectations. Cash of roughly $170 million against a quarterly burn near $58 million supports operations into 2027, meaning further financing could be needed. The market capitalization near $1.3 billion effectively prices in the probability-weighted value of its Phase 3 programs.

USAC. At roughly ~$26.76 per unit, enterprise value lands near ~$6.8 billion, or about ~8.7x the midpoint of guided 2026 Adjusted EBITDA. The trailing P/E near ~25x reads high for an asset-heavy business because depreciation of ~$89.1 million a quarter suppresses net income; guided Distributable Cash Flow of ~$480 million to ~$510 million is closer to ~$3.30 to ~$3.50 per unit, putting the units near ~7.6x to ~8.1x that measure.

Headline figures (approximate, JULY 2026): KOD shows revenue (ttm) ~$0 (no approved products), net loss (q1 2026) ~$58M, r&d expense (q1 2026) ~$49M, cash & equivalents (mar 2026) ~$170M; USAC shows revenue (ttm) ~$1.18B, q2 2026 revenue ~$342.1M (+~37% YoY), q2 2026 adjusted ebitda ~$193.2M (~56.5% margin), 2026 adjusted ebitda guidance ~$770M to ~$800M.

KOD and USAC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KOD and USAC exposure against your real portfolio. It is not an investment adviser.